Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.

The document explores the impact of genetic profiles and treatment on outcomes and hematological toxicity in CEBPA-mutated AML patients. The study analyzes a cohort of 50 intensively treated patients, focusing on baseline characteristics and treatment details. Results show delayed hematopoietic recovery in CEBPA-mutated patients with additional mutations, suggesting the need to incorporate NGS data for therapeutic management. The study highlights the importance of limiting anthracycline dosage to reduce hematological toxicity and improve treatment adherence in this patient population. [Extracted from the article]